Esketamine Receives Support from 2 FDA Committees

Esketamine, a drug developed by Johnson & Johnson for the treatment of depression has received support from two FDA committees. Final FDA approval is expected by March 2019. The drug has been approved for use in treatment resistant depression. From the...

Treatment Resistant Depression Clinical Trials Maryland

We are a clinical trials center located in Gaithersburg, Maryland. We work with patients nationwide, and provide transportation to eligible research participants within the Baltimore-Washington DC Metro Area.Depression is a difficult and painful condition; one that...
Translate »